
An international team of researchers led by Dr. Eleanor Fish, Scientist Emeritus at the Toronto General Hospital Research Institute, UHN, and professor in the University of Toronto‘s Department of Immunology, has shown for the first time that an antiviral drug can help speed up the recovery of COVID-19 patients.
According to the new study, published Friday in Frontiers in Immunology, treatment with interferon(IFN)- a2b may significantly accelerate virus clearance and reduce levels of inflammatory proteins in COVID-19 patients.
The research team found that treatment with this drug, which has been used clinically for many years, significantly reduced the duration of detectable virus in the upper respiratory tract, on average by about seven days. It also reduced blood levels of interleukin(IL)-6 and C-reactive protein (CRP), two inflammatory proteins found in COVID-19 patients.
Dr. Fish says the research team considered IFN-a therapy for COVID-19 after they demonstrated interferon provided therapeutic benefit during the SARS outbreak of 2002 and 2003.
“Rather than developing a virus-specific antiviral for each new virus outbreak, I would argue that we should consider interferons as the ‘first responders’ in terms of treatment,” says Dr. Fish.
“Interferons have been approved for clinical use for many years, so the strategy would be to ‘repurpose’ them for severe acute virus infections.”
Boosting a natural defence mechanism
Interferons are a group of signaling proteins released by the human body in response to all viruses. As Dr. Fish explains, they are a “first line of defence.”
They target different stages of a virus’s life cycle, inhibiting them from multiplying. They also boost an immune response by activating different immune cells to clear an infection. Some viruses, however, can block this natural defense mechanism.
“But it is possible to override this block. If a virus blocks interferon production, then treating with interferon can offset this.”
Study details
The researchers conducted this exploratory study on a group of 77 patients with COVID-19 in Wuhan, China. These patients were admitted to Union Hospital, Tongii Medical College, between January 16 and February 20, 2020. They represented moderate cases of the disease as none of the patients required intensive care or prolonged oxygen supplementation or intubation.
Despite the study’s limitations of a small, non-randomized group of patients, the work provides several important and novel insights into COVID-19 disease, notably that treatment with IFN-a2b can accelerate viral clearance from the upper respiratory tract and also reduce circulating levels of inflammatory factors that are associated with severe COVID-19.
Dr. Fish says a randomized clinical trial is a crucial next step. According to her, a clinical trial with a larger group of infected patients who are randomized to treatment or placebo would further this research.
In the meantime, the findings from this study are the first to suggest therapeutic efficacy of IFN-a2b as an available antiviral intervention for COVID-19, which may also benefit public health measures by shortening the duration of viral clearance and therefore slowing the tide of the pandemic.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Recovery of COVID-19 patients
- COVID-19: Shortness Of Breath, Fatigue, Mental Issues Observed In Recovered Patients
According to ICMR, dyspnea, fatigue, and mental health issues were reported among COVID-19 patients at 1st follow-up of 30-60 days of discharge.
- COVID-19 in Maryland: Map, new case data, vaccine facts
Tuesday, Mar. 21, 2023Sign up for our NewslettersThe following COVID-19 data is provided daily by the Maryland Department of Health. NOTE ABOUT WEEKENDS: MDH now providing COVID-19 data only on ...
- After 33,000 COVID-19 deaths, many Arizonans struggle with mental health
A mental health crisis created over the past three years could have long-term public health consequences, including shorter lifespans.
- Cory Franklin and Robert Weinstein: The health of Americans is a big reason for our high COVID-19 death rate
Unless we address the poor health of Americans, all efforts at planning for the next pandemic are destined to fall short.
- 300+ COVID-19 patients discharged last week; Virginia hospitalizations down 18%
More than 300 additional COVID-19 patients were discharged from Virginia hospitals over the past week, according to the Virginia Hospital & Healthcare Association.
Go deeper with Google Headlines on:
Recovery of COVID-19 patients
[google_news title=”” keyword=”recovery of COVID-19 patients” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Antiviral drug
- FNDR and DevsHealth announce a collaboration to discover and develop affordable drugs for mosquito-borne infections using AI/ML technology
Thanks to its technological platform, DevsHealth reduces the risk, time and investment needed in the development of antibacterial and antiviral drugs. The company was founded in July 2021 with the ...
- COVID antiviral Paxlovid steps closer to full FDA approval
A federal advisory panel recommended Food and Drug Administration approval for Paxlovid on Thursday, more than a year after the agency authorized the antiviral under emergency use. The Antimicrobial ...
- Direct-acting Antiviral Drugs Market 2023 Increasing Popularity Globally to Boost Industry Growth by 2027 | Research Reports World
The Direct-acting Antiviral Drugs Market (2023-2027) Updated Latest Research Report analyzes the market's various ...
- The People's Pharmacy: Could an anti-herpes drug help against dementia?
QUESTION: I’ve had herpes for over 35 years and taken acyclovir to suppress it for nearly that long. When I miss my medication, I can perceive cognitive impairment. It clearly ...
- Global Antiviral Drugs Market Trend 2023-2028, With New Survey
Report Highlights with 121 pages: -"The global Antiviral Drugs market size was valued at USD 44169.08 million in 2022 ...
Go deeper with Google Headlines on:
Antiviral drug
[google_news title=”” keyword=”antiviral drug” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]